In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy
Triple negative breast cancer (TNBC) lack effective therapies. Here, through an in vivo genome-wide CRISPR screen in TNBCs, the authors identify tumorigenic functions for components of the mTORC1/2 complex and of the YAP/Hippo pathway, and demonstrate that pharmacological inhibition of mTOR and YAP...
Guardado en:
Autores principales: | Meiou Dai, Gang Yan, Ni Wang, Girija Daliah, Ashlin M. Edick, Sophie Poulet, Julien Boudreault, Suhad Ali, Sergio A. Burgos, Jean-Jacques Lebrun |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/38501aae84394eee911b035fc5797ebd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability
por: Niklas Gremke, et al.
Publicado: (2020) -
Nanotechnology-Based Targeting of mTOR Signaling in Cancer
por: Yoon MS
Publicado: (2020) -
PPDPF alleviates hepatic steatosis through inhibition of mTOR signaling
por: Ning Ma, et al.
Publicado: (2021) -
The mTOR pathway is necessary for survival of mice with short telomeres
por: Iole Ferrara-Romeo, et al.
Publicado: (2020) -
mTOR-dependent phosphorylation controls TFEB nuclear export
por: Gennaro Napolitano, et al.
Publicado: (2018)